Santen Pharmaceutical Co., Ltd.
Santen Pharmaceutical Co., Ltd. (SNPHY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
snphy · pe ratio · data through Mar 31, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Santen Pharmaceutical Co., Ltd. (SNPHY) measures how much investors pay for each dollar of the company's trailing earnings. SNPHY's current PE ratio of 17.02x is calculated by dividing its stock price of $12.15 by its TTM earnings per share of $114.95. −45.3% discount vs 5Y avg 31.1x
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-03-31
PE Ratio History
2007 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 19 fiscal years · Front-end computedMinQ1 · 25%30.0x
MedianQ3 · 75%89.8x
Max
At 17.02x, SNPHY's current P/E is lower than in 16% of its annual fiscal year readings over the past 19 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - General · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Santen Pharmaceutical Co., Ltd.You SNPHY | $3.9B | 17.02x | +25.3% | $114.95 |
 Bavarian Nordic A/S BVNKF | $2.3B | 10.67x | -21.5% | $17.59 |
 Haw Par Corporation Limited HAWPF | $2.7B | 13.12x | -3.4% | $1.20 |
 Haw Par Corporation Limited HAWPY | $3.0B | 13.84x | +1.9% | $4.72 |
 MediPal Holdings Corporation MAHLY | $3.9B | 12.80x | -5.7% | $219.14 |
 MediPal Holdings Corporation MEPDF | $3.8B | 14.50x | +6.7% | $207.98 |
 Sundrug Co.,Ltd. SDGCF | $3.3B | 16.56x | +21.9% | $270.05 |
Industry Average 6 peers with valid PE | — | 13.58x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-03-31Latest FY2026 | 14.59x | $120.94 | +6.9% | |
2025-03-31 FY2025 | 13.65x | $104.00 | -30.2% | |
2024-03-31 FY2024 | 19.57x | $72.62 | — | |
2023-03-31 FY2023 | — | $-38.58 | — | |
2022-03-31 FY2022 | 17.83x | $68.08 | -80.2% | |
2021-03-31 FY2021 | 89.84x | $17.10 | +191.1% | |
2020-03-31 FY2020 | 30.87x | $59.17 | +43.6% | |
2019-03-31 FY2019 | 21.50x | $78.67 | +10.3% | |
2018-03-31 FY2018 | 19.50x | $86.76 | -36.0% | |
2017-03-31 FY2017 | 30.48x | $52.94 | +136.1% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Santen Pharmaceutical Co., Ltd. (SNPHY) measures how much investors pay for each dollar of the company's trailing earnings. SNPHY's current PE ratio of 17.02x is calculated by dividing its stock price of $12.15 by its TTM earnings per share of $114.95.
Frequently asked questions
SNPHY pe ratio · 6 questionsSNPHY's current PE ratio is 17.02x as of 2026-06-09, based on a stock price of $12.15 and TTM EPS of $114.95. Data sourced from Financial Modeling Prep via SNPHY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Santen Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09